Upstream / Downstream

Explore pathways related to this product.

Antibody Guarantee

CST Antibody Performance Guarantee

LEARN MORE  

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

Product Includes Quantity Applications Reactivity MW(kDa) Isotype
Phospho-cdc2 (Tyr15) (10A11) Rabbit mAb 4539 40 µl
H M R Mk 34 Rabbit IgG
Phospho-Chk1 (Ser345) (133D3) Rabbit mAb 2348 40 µl
H M R Mk 56 Rabbit IgG
Phospho-Chk2 (Thr68) (C13C1) Rabbit mAb 2197 40 µl
H Mk 62 Rabbit IgG
Phospho-Rb (Ser807/811) (D20B12) XP® Rabbit mAb 8516 40 µl
H M R Mk 110 Rabbit IgG
Phospho-Rb (Ser795) Antibody 9301 40 µl
H R Mk 110 Rabbit 
Phospho-p53 (Ser15) (16G8) Mouse mAb 9286 40 µl
H 53 Mouse IgG1
Anti-rabbit IgG, HRP-linked Antibody 7074 100 µl
All Goat 
Anti-mouse IgG, HRP-linked Antibody 7076 100 µl
All Horse 

Product Description

The Cell Cycle/Checkpoint Antibody Sampler Kit provides a fast and economical means of evaluating multiple proteins involved in the cell cyle and checkpoint control. The kit contains enough primary and secondary antibody to perform four Western blot experiments.


Specificity / Sensitivity

Phospho-cdc2 (Tyr15) (10A11) Rabbit mAb detects endogenous levels of cdc2 protein only when phosphorylated at tyrosine 15. Based on sequence similarity, the antibody may cross-react with CDK2 and CDK3. Phospho-Chk2 (Thr68) (C13C1) Rabbit mAb detects endogenous levels of Chk2 only when phosphorylated at Thr68. Phospho-Chk1 (Ser345) Antibody detects Chk1 only when phosphorylated at Ser345 and does not cross-react with other proteins. Phospho-Rb (Ser795) Antibody detects Rb only when phosphorylated at Ser795 and does not cross-react with Rb phosphorylated at other sites. Phospho-Rb (Ser807/811) (D20B12) XP® Rabbit mAb recognizes endogenous levels of Rb protein only when phosphorylated at Ser807, Ser811, or at both sites. This antibody does not cross-react with Rb phosphorylated at Ser608. Phospho-p53 (Ser15) (16G8) Mouse mAb detects endogenous levels of p53 only when phosphorylated at Ser15. The antibody does not cross-react with p53 phosphorylated at other sites.


Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding Ser795 of human Rb. Polyclonal antibodies are purified by protein A and peptide affinity chromatography. Monoclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ser807/811 of human Rb protein, residues surrounding Ser345 of human Chk1, residues surrounding Ser15 of human p53, residues surrounding Tyr15 of human cdc2, and residues surrounding Thr68 of human Chk2.

The cell division cycle demands accuracy to avoid the accumulation of genetic damage. This process is controlled by molecular circuits called "checkpoints" that are common to all eukaryotic cells (1). Checkpoints monitor DNA integrity and cell growth prior to replication and division at the G1/S and G2/M transitions, respectively. The cdc2-cyclin B kinase is pivotal in regulating the G2/M transition (2,3). Cdc2 is phosphorylated at Thr14 and Tyr15 during G2-phase by the kinases Wee1 and Myt1, rendering it inactive. The tumor suppressor protein retinoblastoma (Rb) controls progression through the late G1 restriction point (R) and is a major regulator of the G1/S transition (4). During early and mid G1-phase, Rb binds to and represses the transcription factor E2F (5). The phosphorylation of Rb late in G1-phase by CDKs induces Rb to dissociate from E2F, permitting the transcription of S-phase-promoting genes. In vitro, Rb can be phosphorylated at multiple sites by cdc2, cdk2, and cdk4/6 (6-8). DNA damage triggers both the G2/M and the G1/S checkpoints. DNA damage activates the DNA-PK/ATM/ATR kinases, which phosphorylate Chk at Ser345 (9), Chk2 at Thr68 (10) and p53 (11). The Chk kinases inactivate cdc25 via phosphorylation at Ser216, blocking the activation of cdc2.


1.  Nurse, P. (1997) Cell 91, 865-7.

2.  Watanabe, N. et al. (1995) EMBO J. 14, 1878-1891.

3.  Sherr, C.J. (1996) Science 274, 1672-7.

4.  Norbury, C. and Nurse, P. (1992) Annu Rev Biochem 61, 441-70.

5.  Zhao, H. and Piwnica-Worms, H. (2001) Mol Cell Biol 21, 4129-39.

6.  Dyson, N. (1998) Genes Dev 12, 2245-62.

7.  Matsuoka, S. et al. (2000) Proc. Natl. Acad. Sci. USA 97, 10389-10394.

8.  Lundberg, A.S. and Weinberg, R.A. (1998) Mol Cell Biol 18, 753-61.

9.  Tibbetts, R.S. et al. (1999) Genes Dev. 13, 152-157.

10.  Kitagawa, M. et al. (1996) EMBO J 15, 7060-9.

11.  Harbour, J.W. et al. (1999) Cell 98, 859-69.


Entrez-Gene Id 983, 1111, 11200, 7157, 5925
Swiss-Prot Acc. P06493, O14757, O96017, P04637, P06400

Protein Specific References

Smits VA et al. (2000) J Biol Chem 275, 30638–43

Casagrande F and Darbon JM (2001) Biochem Pharmacol 61, 1205–15

Yarden RI et al. (2002) Nat Genet 30, 285–9

Lee S et al. (2002) Cancer Res 62, 5703–10

Chao JI et al. (2004) J Biol Chem 279, 20267–76

Xiao D et al. (2004) Mol Cancer Ther 3, 567–75

Normand G et al. (2005) J Biol Chem 280, 7118–30

Wang G et al. (2005) Cell Mol Life Sci 62, 881–93

Yamaura M et al. (2009) Cancer Res 69, 2647–54

Olsen BB et al. (2010) Int J Oncol 36, 1175–82

Zhang YW et al. (2005) Mol Cell 19, 607–18

Singh B et al. (2007) J Surg Res 140, 220–6

Matsumoto M et al. (2007) J Cell Sci 120, 1104–12

Zhang YW et al. (2009) Mol Cell 35, 442–53

Xu N et al. (2011) Biochem Biophys Res Commun 413, 465–70

Ahn JY et al. (2000) Cancer Res 60, 5934–6

Ahn J and Prives C (2002) J Biol Chem 277, 48418–26

Xu X et al. (2002) Mol Cell Biol 22, 4419–32

Lou Z et al. (2003) Nature 421, 957–61

Tsvetkov L et al. (2003) J Biol Chem 278, 8468–75

Bartkova J et al. (2004) Oncogene 23, 8545–51

Yin MB et al. (2004) Mol Pharmacol 66, 153–60

Li J and Stern DF (2005) J Biol Chem 280, 12041–50

Buscemi G et al. (2006) Mol Cell Biol 26, 7832–45

Yoda A et al. (2006) J Biol Chem 281, 24847–62

Sodha N et al. (2006) Cancer Res 66, 8966–70

Kass EM et al. (2007) J Biol Chem 282, 30311–21

Oliva-Trastoy M et al. (2007) Oncogene 26, 1449–58

Gabant G et al. (2008) J Mol Biol 380, 489–503

Guo X et al. (2010) J Biol Chem 285, 33348–57

Chehab NH et al. (1999) Proc Natl Acad Sci U S A 96, 13777–82

Buschmann T et al. (2000) Cancer Res 60, 896–900

Chehab NH et al. (2000) Genes Dev 14, 278–88

Persons DL et al. (2000) J Biol Chem 275, 35778–85

Vaziri H et al. (2001) Cell 107, 149–59

Minamoto T et al. (2001) Oncogene 20, 3341–7

Stewart ZA et al. (2001) Oncogene 20, 113–24

Bean LJ and Stark GR (2001) Oncogene 20, 1076–84

Xie S et al. (2001) J Biol Chem 276, 43305–12

Xie S et al. (2001) J Biol Chem 276, 36194–9

Kim SJ et al. (2002) J Biol Chem 277, 33501–8

Bulavin DV et al. (2002) Nat Genet 31, 210–5

Shono T et al. (2002) Cancer Res 62, 1069–76

Adamson AW et al. (2002) J Biol Chem 277, 38222–9

Hase H et al. (2002) J Biol Chem 277, 46950–8

Bischof O et al. (2002) EMBO J 21, 3358–69

Qin JZ et al. (2002) Oncogene 21, 2991–3002

Hofmann TG et al. (2002) Nat Cell Biol 4, 1–10

Chouinard N et al. (2002) Biochem J 365, 133–45

Shiseki M et al. (2003) Cancer Res 63, 2373–8

Chen K et al. (2003) J Biol Chem 278, 39527–33

Sengupta S et al. (2003) EMBO J 22, 1210–22

Urban G et al. (2003) J Biol Chem 278, 9747–53

Oguchi K et al. (2003) Blood 101, 3622–7

Hideshima T et al. (2003) Blood 101, 1530–4

Lindström MS and Wiman KG (2003) Oncogene 22, 4993–5005

Hofseth LJ et al. (2003) Proc Natl Acad Sci U S A 100, 143–8

Wang C and Chen J (2003) J Biol Chem 278, 2066–71

Matsuoka M et al. (2003) Environ Health Perspect 111, 509–12

Yanamadala S and Ljungman M (2003) Mol Cancer Res 1, 747–54

Möller A et al. (2003) Cancer Res 63, 4310–4

Goudelock DM et al. (2003) J Biol Chem 278, 29940–7

Louria-Hayon I et al. (2003) J Biol Chem 278, 33134–41

Tritarelli A et al. (2004) Mol Biol Cell 15, 3751–7

Mroz RM et al. (2004) Am J Respir Cell Mol Biol 30, 564–8

Rui Y et al. (2004) EMBO J 23, 4583–94

Li Y et al. (2004) Oncogene 23, 7355–65

Vaghefi H and Neet KE (2004) Oncogene 23, 8078–87

Nair VD et al. (2004) J Biol Chem 279, 27494–501

Takagi M et al. (2004) Blood 103, 283–90

Ito K et al. (2004) Cancer Res 64, 1071–8

Koutsodontis G and Kardassis D (2004) Oncogene 23, 9190–200

Jackson MW et al. (2004) Oncogene 23, 4477–87

Dohoney KM et al. (2004) Oncogene 23, 49–57

Thompson T et al. (2004) J Biol Chem 279, 53015–22

Yeh PY et al. (2004) Oncogene 23, 3580–8

Komiyama S et al. (2004) Biochem Biophys Res Commun 323, 816–22

Soubeyrand S et al. (2004) Eur J Biochem 271, 3776–84

Ou YH et al. (2005) Mol Biol Cell 16, 1684–95

Feki A et al. (2005) Oncogene 24, 3726–36

Li Z et al. (2005) J Biol Chem 280, 16843–50

Di Stefano V et al. (2005) Oncogene 24, 5431–42

Hershko T et al. (2005) Cell Death Differ 12, 377–83

Mayo LD et al. (2005) J Biol Chem 280, 25953–9

Wesierska-Gadek J et al. (2005) Mol Cancer Ther 4, 113–24

Wang L et al. (2005) Oncogene 24, 3020–7

Zhao Y et al. (2006) Mol Cell Biol 26, 2782–90

Gresko E et al. (2006) EMBO J 25, 1883–94

Ichwan SJ et al. (2006) Oncogene 25, 1216–24

Knights CD et al. (2006) J Cell Biol 173, 533–44

Moiseeva O et al. (2006) Mol Biol Cell 17, 1583–92

Zeng PY and Berger SL (2006) Cancer Res 66, 10701–8

Li AG et al. (2006) Mol Cell 23, 575–87

Yoshida K et al. (2006) J Biol Chem 281, 5734–40

Li DW et al. (2006) Oncogene 25, 3006–22

Fraser M et al. (2006) Oncogene 25, 2203–12

Paulsen MT et al. (2006) Mol Cancer 5, 25

Singh K et al. (2007) PLoS One 2, e660

Nag A et al. (2007) J Biol Chem 282, 8812–20

Li HH et al. (2007) EMBO J 26, 402–11

Li Q et al. (2007) Cancer Res 67, 66–74

Taira N et al. (2007) Mol Cell 25, 725–38

Lambrot R et al. (2007) J Clin Endocrinol Metab 92, 2632–9

Ivanov GS et al. (2007) Mol Cell Biol 27, 6756–69

Nakanishi M et al. (2007) J Biol Chem 282, 22993–3004

Liu Y et al. (2007) J Biol Chem 282, 2505–11

Derheimer FA et al. (2007) Proc Natl Acad Sci U S A 104, 12778–83

Lee JH et al. (2007) J Cell Sci 120, 2259–71

Mantovani F et al. (2007) Nat Struct Mol Biol 14, 912–20

Wang H et al. (2008) J Biol Chem 283, 2564–74

Sun L et al. (2008) J Exp Clin Cancer Res 27, 35

Chang PC and Li M (2008) J Virol 82, 278–90

Lin T et al. (2008) Toxicology 247, 145–53

Chen JJ et al. (2008) J Immunol 180, 8030–9

Shouse GP et al. (2008) Mol Cell Biol 28, 448–56

Kitagawa M et al. (2008) Mol Cell 29, 217–31

Habold C et al. (2008) J Cell Mol Med 12, 607–21

Zhu H et al. (2008) Int J Cancer 123, 2741–9

Yamaguchi H et al. (2009) J Biol Chem 284, 11171–83

Wang Z et al. (2009) Pharm Res 26, 1140–8

Bar JK et al. (2009) Int J Gynecol Cancer 19, 1322–8

Nishimura T et al. (2009) J Biol Chem 284, 36442–52

Puca R et al. (2009) Mol Cancer 8, 85

Yadavilli S et al. (2009) J Biochem Mol Toxicol 23, 373–86

Baxter EW and Milner J (2010) J Neurooncol 97, 373–82

Fraser JA et al. (2010) J Biol Chem 285, 37773–86

Fraser JA et al. (2010) J Biol Chem 285, 37762–72

Shang X et al. (2010) Oncogene 29, 4938–46

Chen X et al. (2010) J Biol Chem 285, 12823–30

Kawano T et al. (2010) Int J Oncol 37, 787–95

Moehlenbrink J et al. (2010) Cancer Lett 292, 119–24

Venerando A et al. (2010) Cell Mol Life Sci 67, 1105–18

Puca R et al. (2010) Free Radic Biol Med 48, 1338–46

Marchenko ND et al. (2010) Cell Death Differ 17, 255–67

Aranha MM et al. (2011) PLoS One 6, e21396

Muñoz-Fontela C et al. (2011) Cell Cycle 10, 3701–5

Wu L et al. (2011) J Biol Chem 286, 2236–44

Ozeki C et al. (2011) J Biol Chem 286, 18251–60

Mellert HS et al. (2011) J Biol Chem 286, 4264–70

Valbuena A et al. (2011) PLoS One 6, e17320

Xu S et al. (2011) J Cardiovasc Pharmacol 58, 263–71

Seo SK et al. (2011) J Thorac Oncol 6, 1313–9

Savelyeva I and Dobbelstein M (2011) Oncogene 30, 865–75

Wu ZZ et al. (2011) J Cell Physiol 226, 2415–28

Smeenk L et al. (2011) PLoS One 6, e17574

Grison A et al. (2011) Proc Natl Acad Sci U S A 108, 17979–84

Gully CP et al. (2012) Proc Natl Acad Sci U S A 109, E1513–22

Wang H et al. (2012) DNA Repair (Amst) 11, 146–56

Xu S et al. (2013) Cell Res 23, 423–35

Chan C et al. (2013) Mol Cell Biol 33, 485–97

Thakur BK et al. (2013) Int J Cancer 132, 766–74

Yang Y et al. (2013) J Biol Chem 288, 529–39

Panigone S et al. (2000) Oncogene 19, 4035–41

Brantley MA Jr and Harbour JW (2000) Cancer Res 60, 4320–3

Chan HM et al. (2001) Nat Cell Biol 3, 667–74

Taneja SS et al. (2001) J Cell Biochem 84, 188–99

Schroeder MD et al. (2002) Mol Endocrinol 16, 45–57

Balasenthil S and Vadlamudi RK (2003) J Biol Chem 278, 22119–27

Huang H et al. (2004) Oncogene 23, 2161–76

Benzeno S et al. (2004) Cancer Res 64, 3885–91

Hamdane M et al. (2005) J Cell Sci 118, 1291–8

Youn CK et al. (2005) Nat Cell Biol 7, 137–47

Leibundgut K et al. (2005) Stem Cells 23, 1002–11

Schmitz NM et al. (2005) Leukemia 19, 1783–7

Wallick CJ et al. (2005) Oncogene 24, 5606–18

Roesch A et al. (2005) Mod Pathol 18, 565–72

Swarbrick A et al. (2005) Oncogene 24, 381–9

Ledl A et al. (2005) Oncogene 24, 3810–8

Schmitz NM et al. (2006) Am J Pathol 169, 1074–9

Inoue Y et al. (2007) EMBO J 26, 2083–93

Park Y et al. (2008) Cell Cycle 7, 2384–91

Chang TW et al. (2008) Oncogene 27, 332–8

Boulay PL et al. (2011) Oncogene 30, 3846–61

Sen S et al. (2011) J Biol Chem 286, 36580–91

Lentine B et al. (2012) Cell Cycle 11, 3324–30


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.
U.S. Patent No. 5,675,063.